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The hedgehog signaling cascade is an evolutionarily conserved pathway that regulates multiple aspects of embryonic devel-
opment and plays a decisive role in tissue homeostasis. As the best studied member of three hedgehog ligands, sonic hedgehog 
(Shh) is known to be associated with kidney development and tissue repair after various insults. Recent studies uncover an in-
trinsic link between dysregulated Shh signaling and renal fibrogenesis. In various types of chronic kidney disease (CKD), Shh 
is upregulated specifically in renal tubular epithelium but targets interstitial fibroblasts, thereby mediating a dynamic epitheli-
al-mesenchymal communication (EMC). Tubule-derived Shh acts as a growth factor for interstitial fibroblasts and controls a 
hierarchy of fibrosis-related genes, which lead to the excessive deposition of extracellular matrix in renal interstitium. In this 
review, we recapitulate the principle of Shh signaling, its activation and regulation in a variety of kidney diseases. We also 
discuss the potential mechanisms by which Shh promotes renal fibrosis and assess the efficacy of blocking this signaling in 
preclinical settings. Continuing these lines of investigations will provide novel opportunities for designing effective therapies 
to improve CKD prognosis in patients. 
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It is estimated that the prevalence of chronic kidney disease 
(CKD) is about 10%–12% of the adult population world-
wide (Coresh et al., 2007; Zhang et al., 2012; Zoccali et al., 
2010). As a general rule, tissue fibrosis develops in virtually 
every form of CKD, as both a consequence and a character-
istic feature of disease progression. From a cell biological 
standpoint, the intricate process of renal fibrosis has been 
linked, more or less, to an inappropriate activation of some 
key signaling pathways, such as transforming growth fac-
tor- (TGF-), renin-angiotensin system (RAS), Wnt/- 
catenin, and sonic hedgehog (Shh) (He and Dai, 2015; 
Meng et al., 2015; Santos et al., 2012; Sweetwyne et al., 
2014; Tan et al., 2014). Most of the time, these diverse sig-
nals reciprocally crosstalk through cell-to-cell communica-
tion that involves all resident cells in the kidney, as well as 
the infiltrating cells (Duffield, 2014; Liu, 2011; Zeisberg 
and Neilson, 2010). In the past several years, the role and 
mechanisms of TGF-, RAS and Wnt/-catenin signaling in 
the pathogenesis of CKD have been well documented 
(Meng et al., 2015; Sweetwyne et al., 2014; Tan et al., 
2014; Zhou et al., 2015). Therefore, the scope of the present 
review is focused on our current understanding of Shh sig-
naling in renal fibrogenesis.  
Hedgehog signaling is an evolutionarily conserved,  
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developmental pathway that plays an essential role in regu-
lating mammalian embryonic development (Robbins et al., 
2012). Hedgehog was identified in genetic screens in Dro-
sophila in 1980, and the vertebrate hedgehog proteins were 
discovered in 1993 (Krauss et al., 1993; Nusslein-Volhard 
and Wieschaus, 1980). Since then, investigations on the role 
of hedgehog signaling in organ development and diseases 
progression have rapidly accelerated. There are three 
hedgehog ligands in mammals: Sonic hedgehog (Shh),  
Indian hedgehog (Ihh) and Desert hedgehog (Dhh), of 
which Shh is the best characterized (Lum and Beachy, 
2004). Accumulating studies have demonstrated an activat-
ed Shh signaling in fibrotic CKD, suggesting a potential 
connection between aberrant regulation of this signaling and 
kidney fibrosis (Ding et al., 2012; Fabian et al., 2012; Kramann 
et al., 2015; Rauhauser et al., 2015; Zhou et al., 2014).  
In this review, we will summarize the key features of Shh 
signaling and its regulation in various forms of CKD, and 
discuss the targets and the modes of action of Shh, as well 
as its relevant signal transduction routes. We will also pro-
vide the perspectives of several strategies to intervene Shh 
signaling for an effective therapy of the patients with fi-
brotic CKD.  
SONIC HEDGEHOG SIGNALING: 
COMPONENTS, ROUTES AND MECHANISM  
Shh ligand 
As a morphogen, Shh is important in tissue patterning dur-
ing embryonic development by controlling multiple biolog-
ical processes including cell fate determination, cell prolif-
eration and differentiation (Gill and Rosenblum, 2006;  
Pan et al., 2013). Human Shh is synthesized as a 45 kD 
precursor protein with 462 amino acids, in which the first 
23 amino acids serves as a signal peptide. It is autocatalyti-
cally cleaved to produce a 19 kD amino-terminal fragment 
(N-Shh) and a 25 kD carboxyl-terminal domain (C-Shh), 
and then secreted into the extracellular space. N-Shh retains 
all known signaling capabilities, while C-Shh possesses 
protease activity.  
During the cleavage, a cholesterol molecule is added to 
the carboxyl end of the N-terminal domain, which is in-
volved in trafficking, secretion and receptor interaction of 
the Shh ligand (Figure 1A). Typically, secreted Shh con-
tains two covalent modifications, a C-terminal cholesterol 
moiety and a palmitoyl group to the N-terminal of the pro-
cessed N-Shh. Despite its dual lipid modification and tight 
association with cell membranes, the Shh protein acts di-
rectly on distant cells in developing tissues. In vertebrates, 
this remote action requires the transmembrane trans-
porter-like protein Dispatched (Disp) and Skinny hedgehog 
(Skn), which mediate the release of Shh from secreting cells 
(Lum and Beachy, 2004). Shh elicits its biological activity 
via both an autocrine and paracrine fashion.  
Canonical Shh signaling 
Shh transduces its signaling across the plasma membrane in 
the responding cells via either the canonical or non- 
canonical pathways. Canonical Shh signaling is the major 
pathway which has been studied intensively in vertebrate 
embryogenesis and tumorigenesis over the past few decades 
(Lum and Beachy, 2004). When secreted Shh ligand reaches 
its target cell, it binds with high affinity to the cell surface 
receptor, a twelve-pass transmembrane protein Patched-1 
(Ptch1), to initiate the signal (Ingham, 2012). In the absence 
of Shh, Ptch1 normally represses the activity of Smooth-
ened (Smo), the seven-pass transmembrane spanning re-
ceptor which is the major signaling component and switch 
in this pathway. The zinc-finger transcriptional factors of 
Glioma-associated oncogenes (Gli) family are inhibited by 
the cytoplasmic protein Suppressor of Fused (SuFu) 
(Tukachinsky et al., 2010). Conversely, in the presence of 
Shh binding to Ptch1, there is relief of the inhibition of 
Smo. Accumulated Smo receptor turns on a complex net-
work leading to the regulation of three Gli transcriptional 
factors, the activators Gli1 and Gli2 and the repressor Gli3. 
Activated Gli accumulates in the nucleus and then controls 
the transcription of target genes, such as cyclin D1, cyclin E 
and N-Myc. Of note, besides acting as a transcriptional re-
pressor mediated by a truncated fragment, Gli3 exists as a 
full length form which is able to activate transcription in 
specific systems (Dai et al., 2002).  
In mammals, Ptch1 has a homologue Ptch2 that shares 
54% sequence identity (Carpenter et al., 1998). All three 
mammalian hedgehog ligands bind both Ptch1 and Ptch2 
receptors with similar affinity, making it difficult to dis-
criminate the receptor specificity. However, Ptch2 appears 
to have a distinct downstream signaling role from Ptch1, as 
it is expressed at much higher levels in specific organs such 
as testis and ovary (O’Hara et al., 2011). In the absence of 
ligand binding, Ptch2 has a decreased ability to inhibit the 
activity of Smo, compared with Ptch1 (Alfaro et al., 2014; 
Zhulyn et al., 2015). Structurally, Ptch protein has a sterol 
sensing domain (SSD), which is essential for inhibiting the 
activity of Smo (Lindstrom et al., 2006). Normally, Ptch 
acts as a sterol pump and removes oxysterols produced by 
7-dehydrocholesterol reductase. Upon binding of Shh pro-
tein or a mutation in the SSD of Ptch, the pump is turned 
off, which allows oxysterols to accumulate around Smo. 
This accumulation of sterols renders Smo to become active 
or stay on the membrane for a longer period of time 
(Reichrath and Reichrath, 2013). In contrast to Drosophila, 
vertebrates possess another level of hedgehog regulation 
through ligand-dependent antagonism mediated by 
Hh-interacting protein 1 (Hhip1). Hhip and Smo colocalize 
at the cell surface, Hhip has no effect on activity of Smo but 
modulates Smo localization. In addition, Hhip1 also se-
questers hedgehog ligands (Ochi et al., 2006; Zhao et al., 
2014).  
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Figure 1  Schematic illustration of the Shh signaling pathway. A, In Shh-producing cells, the Shh precursor is proteolytically cleaved to generate the N-Shh 
in the endoplasmic reticulum (ER). Secreted Shh contains two covalent cholesterol modifications: a C-terminal cholesterol moiety and a palmitoyl group is 
added at the N-terminus. Skn and Dispatched, mediate the release of Shh ligand. B, The canonical Shh signaling. In the inactive state, the transmembrane 
protein receptor Ptch1 interacts with and inhibits the activity of a seven transmembrane protein, Smo. Interactions with cytoplasmic proteins, including Fused 
and Sufu, the transcription factors Gli are prevented from entering the nucleus and downstream target genes expression are repressed. In the active state, Shh 
binding to Ptch1, which allows Smo activation, thereby activating the cascade that leads to the Gli transcription factors to exert their effects in the nucleus. C, 
The non-canonical Shh signaling. There are two types of non-canonical Shh signaling pathways, one is Ptch1-dependent which regulates cell apoptosis and 
proliferation, the second is Smo-dependent which associate with modulation of actin cytoskeleton-dependent processes. Shh, Sonic hedgehog. N-Shh, 
N-terminal Sonic hedgehog. Skn, Skinny hedgehog. Ptch1, Patched-1. Smo, Smoothened. Hhip1, Hedgehog-interacting protein 1. Fu, Fused. Sufu, Suppres-
sor of fused. Gli, Glioma-associated oncogenes.  
Non-canonical Shh signaling 
It is increasingly recognized that not all Shh signaling pro-
ceeds through Gli protein activation, thanks to the studies in 
the fields of cancer biology, neurological disorders and 
metabolic diseases (Aberger et al., 2012; Jenkins, 2009; 
Teperino et al., 2014; Zhao et al., 2010). The definition of 
“non-canonical Shh signaling” refers to the cellular  
responses to Shh ligand that are independent of the activa-
tion of the Gli family of transcription factors. At least two 
separate non-canonical Shh signaling pathways are charac-
terized: one is through Ptch1 but is unrelated to its inhibi-
tion on Smo; another is through Smo but is beyond Gli  
regulation (Figure 1C) (Brennan et al., 2012).  
In the non-canonical Shh signaling engaged by Ptch1, 
Ptch1 is shown to independently induce human embryonic 
kidney 293T cells apoptosis provoked by Shh deprivation 
(Thibert et al., 2003). However, overexpression of Smo 
could not protect against cell death. Structurally, the 
C-terminal cytoplasmic domain of Ptch1 is a substrate for 
caspase-3, -7, and -8. Cleavage of Ptch1 is critical for 
apoptosis because mutation in the caspase site abolishes 
Ptch1-induced cell death. In addition, Ptch1 undergoes pro-
teolytic processing at the C-terminus and the soluble 
C-terminal domain (CTD) translocates to the nucleus and 
mediates a new form of signal transduction (Kagawa et al., 
2011). Different from Drosophila (Johnson et al., 2000), the 
CTD is not required for the canonical signal transduction 
but most likely has a distinct function in apoptosis and/or 
proliferation in mammals (Makino et al. ,  2001; 
Nieuwenhuis et al., 2007; Thibert et al., 2003). Besides 
apoptosis, exogenous Ptch1 in 293T cells induces the redis-
tribution of cyclin B1 from the nucleus to the cytoplasm,  
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resulting in reduced cell proliferation. This effect could be 
disrupted in the presence of Shh.  
Another non-canonical Shh signaling mainly controls 
endothelial cells cytoskeletal reorganization and fibroblast 
migration through activating small GTPases and regulating 
fluctuations of calcium ions upon stimulation of Shh 
(Chinchilla et al., 2010; El-Zaatari et al., 2010; Polizio et al., 
2011). It has been demonstrated that none of the three 
hedgehog ligands are able to induce Gli-target genes in  
human umbilical vein (HUVeC) or human cardiac micro-
vascular endothelial cells (HMVeC), indicating that endo-
thelial cells do not respond to hedgehog through the canon-
ical pathway. However, all three hedgehog proteins promote 
endothelial cell tubulogenesis in 3D cultures in a Smo-  
dependent manner (Polizio et al., 2011). Consistent with the 
required cytoskeletal rearrangement for tubulogenesis, Shh, 
Ihh and Dhh all stimulate the small GTPase RhoA and actin 
stress fibers formation (Chinchilla et al., 2010). This effect, 
mediated by Smo and G proteins, defines a new non-   
canonical hedgehog pathway. In this system, stimulation by 
hedgehog ligands results in the formation of actin stress 
fibers within minutes, thus suggesting a non-canonical 
pathway based on the time course and the lack of detectable 
Gli-dependent transcription. Reminiscent of cytoskeleton 
remodeling, Shh could activate non-canonical signaling 
pathway to control axon guidance by stimulating the activi-
ty of Src family kinase (Yam et al., 2009).  
SHH SIGNALING AND CKD 
Shh induction and localization in CKD 
Shh is known to be expressed in epithelial cells during  
development of several organs including kidney. In adult 
kidneys, however, Shh expression is largely silenced. 
Re-activation of Shh signaling has been implicated in the 
pathogenesis of tissue fibrosis in many organs including 
kidney, lung and liver (Chung et al., 2016; Cigna et al., 
2012; Zhou et al., 2014).  
As the major constituent of renal parenchyma, kidney 
tubular epithelium is the epicenter of various toxic, ischem-
ic, metabolic and immunologic injuries (Li et al., 2012; 
Zhou et al., 2012). Although the damaged tubular cells may 
undergo a variety of maladaptive changes such as partial 
epithelial-mesenchymal transition (EMT), cell cycle arrest, 
defects in cell metabolism (Grande et al., 2015; Kang et al., 
2015; Liu, 2010; Lovisa et al., 2015), one common conse-
quence of these diverse responses is converting to a secre-
tory phenotype (Zhou and Liu, 2016). Indeed, marked  
induction of Shh protein is observed in the fibrotic kidneys 
in all commonly used CKD models, including folic acid 
(FA), unilateral ureteral obstruction (UUO), ischemia reper-
fusion injury (IRI),  adriamycin (ADR) and 5/6  
nephrectomy, although it is barely detectable in normal kid-
neys (Ding et al., 2012; Fabian et al., 2012; Rauhauser et al., 
2015; Zhou et al., 2014). In human biopsy specimens, Shh is 
also specifically induced in renal tubular epithelium of the dis-
eased kidney, regardless of the initial etiologies (Zhou et al., 
2014). Meanwhile, the sensor receptor Ptch1 and transcrip-
tional factor Gli1, Gli2 are also upregulated in high-grade 
fibrotic human kidneys (Kramann et al., 2015; Zhou et al., 
2014). These results suggest that Shh upregulation is a com-
mon pathologic finding in a wide variety of kidney diseases.  
Shh induction is predominantly localized in renal tubular 
epithelium (Figure 2), whereas interstitial cells in the  
expanded interstitium are largely negative for Shh staining. 
Most importantly, upregulation of Shh protein is an  
extremely early event in different models in vivo, suggest-
ing a potential role for Shh in triggering the first wave of 
defense mechanism after tissue damage. In vitro, a variety 
of pathologic cues such as TGF-1 and Wnt induces Shh 
mRNA expression and protein secretion by tubular epitheli-
al cells. Based on these observations, we recently propose 
that Shh is a novel, inducible, tubule-derived growth factor 
that mediates epithelial-mesenchymal communication (EMC) 
after kidney injury (Ding et al., 2012; Zhou et al., 2014). 
Shh promotes kidney fibrosis  
The functionality of Shh in the development and progres-
sion of CKD has been extensively studied by both gain- and 
loss-of function approaches. Emerging evidence indicates 
that along with the progression of kidney injuries, hyperac-
tive Shh signaling causes fibroblast activation, proliferation 
and matrix over-production by multiple mechanisms, pri-
marily via a mode of epithelial-mesenchymal interaction.  
In mouse model of IRI, overexpression of Shh transgene 
through a hydrodynamic-based gene transfer approach 
promoted fibroblast proliferation and matrix overproduction 
and deposition, ultimately leading to an increased kidney 
fibrosis and aggravated kidney dysfunction (Zhou et al., 
2014). The population of Shh-responsive Gli1-positive cells 
is markedly expanded in renal interstitium after Shh 
transgene expression. In vitro, human recombinant Shh 
protein activated Ptch1 and Gli1 and induced -smooth 
muscle actin (-SMA), desmin, Snail1, fibronectin, and 
collagen I expression (Ding et al., 2012; Zhou et al., 2014), 
suggesting a critical role for Shh signaling in regulating 
myofibroblast activation and matrix production. Shh also 
promotes cultured rat kidney fibroblast proliferation and 
stimulates the induction of numerous proliferation-related 
genes (Zhou et al., 2014). Shh ligand also triggers pericyte- 
like cell proliferation in vitro (Fabian et al., 2012), suggest-
ing a role for this pathway in regulating cell cycle progres-
sion of myofibroblast progenitors during the development 
of renal fibrosis.  
Using conditional knockout mouse model, we recently 
show that tubule-specific deletion of Shh reduces fibrotic 
lesions after kidney injury (data not shown), suggesting that 
Shh not only is sufficient but also necessary for fibrosis 
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Figure 2  Tubule-derived Shh targets interstitial fibroblasts. A–C, Representative micrographs of immunohistochemical staining show marked induction of 
Shh protein after renal ischemia reperfusion injury (IRI) at 1 (B) and 10 days (C), respectively. Shh is barely detectable in sham control (A). At 1 day after 
IRI, Shh expression was significantly induced (B, red arrowhead) in renal tubules. At 10 days, sustained activation of Shh in renal tubules was observed (C, 
red arrowhead). D, Identification of the interstitial fibroblasts as Shh-responsive cells in fibrotic kidneys. Transgenic Gli1-CreERT2 mice were subjected to 
IRI for 10 days, and kidneys subjected to double immunostaining for Cre recombinase (red) and various cell type-specific markers (green). Wide arrows 
indicate cells with positive staining for both vimentin and Cre; arrowheads denote Cre-positive cells; arrows show CD45- or CD31-positive cells. Panel D 
was reproduced from our published paper (Zhou et al., 2014) with permission. E, Schematic diagram shows that Shh mediates epithelial-mesenchymal 
communication between injured tubules and interstitial fibroblasts, leading to fibroblast activation and proliferation, as well as matrix overproduction.  
development in the kidney. This conclusion is also sup-
ported by genetic and pharmacologic manipulations of the 
Shh downstream mediators Smo or Gli proteins. It is shown 
that the kidneys in Gli1-deficient mice are protected against 
the development of tubulointerstitial fibrosis after UUO 
(Ding et al., 2012; Rauhauser et al., 2015). Smo inhibitors 
such as cyclopamine also repress the induction of Gli1, 
Snail1 and -SMA, and reduce matrix expression and miti-
gate fibrotic lesions in obstructive nephropathy (Ding et al., 
2012; Rauhauser et al., 2015), although it does not affect 
renal Shh expression. Another study demonstrates that Gli2 
in Shh pathway is expressed in myofibroblast progenitors, 
and drive cell-cycle progression in cultured mesenchymal 
stem cell-like progenitors (Kramann et al., 2015). Myofi-
broblast-specific deletion of Gli2 or overexpression of Gli3 
repressor attenuates renal fibrosis after UUO (Kramann et al., 
2015). In addition, suppression of Shh signaling is also as-
sociated with decreased macrophage infiltration after ob-
structive injury (Rauhauser et al., 2015).  
TARGETS AND MECHANISM OF SHH 
SIGNALING IN KIDNEY FIBROSIS  
Fibroblasts as a major target of canonical Shh signaling 
Given that Shh is a secreted protein mainly produced by 
renal tubular epithelium, an important question that needs to 
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be clarified is the cellular targets of Shh in diseased kidney. 
To address this issue, three independent groups utilized the 
Gli1lacZ mutant mice, the so-called hedgehog-reporter mice, 
which harbor a -galactosidase (-Gal) “knock-in” muta-
tion. Under the control of the native Gli1 upstream promot-
er/enhancer elements, lacZ expression in these mice authen-
tically recapitulates the expression pattern of the endoge-
nous Gli1 mRNA. Results show that interstitial fibroblasts, 
including platelet-derived growth factor receptor (PDGFR)- 
-positive pericytes, are identified as principal Shh-    
responding cells in vivo in UUO and IRI models (Ding et al., 
2012; Fabian et al., 2012; Rauhauser et al., 2015; Zhou et al., 
2014). Further studies using Gli1-Cre mice have demon-
strated that the Shh-responding cell population does not 
include CD31-positive endothelial cells and CD45- 
positive monocytes in renal interstitium (Zhou et al., 2014) 
(Figure 2D). These findings are consistent with the observa-
tions that cultured kidney fibroblasts respond to Shh stimu-
lation in vitro, leading to an enhanced cell proliferation and 
myofibroblastic activation. Intriguingly, Shh had no effect 
on the proliferation of renal tubular epithelial cells (Zhou et al., 
2014). Therefore, as a tubule-derived growth factor, Shh 
specifically targets interstitial fibroblasts and mediates epi-
thelial-mesenchymal communication via a paracrine fashion 
(Figure 2).  
It should be pointed out that Gli1 expression only reflects 
the activation of the canonical hedgehog signaling in the 
responding cells. In this regard, possibility exists that other 
types of cells in the kidney besides interstitial fibroblasts, 
such as tubular epithelial cells, endothelial cells and infil-
trated inflammatory cells, may also respond to Shh via 
Gli-independent, non-canonical pathway. More studies are 
warranted in this area to define the role and mechanism of 
Shh in regulating the activities of many other kidney cells 
under pathologic conditions.  
Crosstalk with other signaling pathways in kidney 
fibrosis 
Increasing evidence suggests that Shh signal interacts with 
several key signaling pathways and operates in a coordinat-
ed fashion during renal fibrogenesis. For instance, besides 
Shh signaling pathway, TGF-1, Wnt/-catenin and Notch 
pathways are well recognized to play crucial roles in the 
evolution of renal fibrosis in CKD (Bielesz et al., 2010; He  
and Dai, 2015; He et al., 2009; Tan et al., 2014; Zhou et al.,  
2016). However, the role of Shh signaling is quite unique in 
this process in that it specifically targets interstitial cells, 
while it is mainly produced by the injured tubules. In this 
way, Shh acts as a master communicator between the  
injured tubular epithelial cells and interstitial fibroblasts, 
leading to fibroblast activation and expansion, which plays a 
central role in renal fibrogenesis (Fabian et al., 2012; 
Kramann et al., 2015; Zhou et al., 2014). In contrast, the ma-
jor targets of Wnt and Notch signals are tubular epithelial 
cells, which then indirectly promote kidney fibrosis through 
the processes such as partial EMT (Liu, 2006, 2010).  
Over the past several years, evidence of crosstalk among 
Shh, Wnt, Notch, TGF-1 and other signaling pathways has 
been frequently reported in renal fibrosis. For example, Shh 
is known to upregulate Wnt2b and Wnt5a (Katoh and 
Katoh, 2009), as well as Notch ligand Jaggad2 (Katoh and 
Katoh, 2008). Wnts could induce Shh expression in epithe-
lial cells, and both Wnt and Shh signaling can induce Snail1 
expression in fibrotic kidneys (Ding et al., 2012; Wang et al., 
2011; Zhou and Liu, 2015). Gli1 could induce Snail1 and 
promote -catenin nuclear translocation in epithelial cells 
(Li et al., 2007). TGF-1 is reported to induce several key 
components of the Wnt, Shh and Notch signaling pathways 
(Bielesz et al., 2010; Wang et al., 2011). Therefore, cross-
talk between these signal pathways has the potential to or-
chestrate complex cellular responses to extracellular stimuli. 
These findings present new challenges—as well as opportu-
nities—for discovering novel interventional strategies. 
STRATEGIES TO TARGET SHH SIGNALING 
IN KIDNEY FIBROSIS 
In view of the central role of Shh signaling in renal fibrosis, 
targeting this pathway might be an effective strategy to halt 
and even to reverse the progression of CKD. In theory, the 
Shh signaling could be blocked at different levels along the 
signal transduction route. Recently published literature de-
scribes small molecule inhibitors in Shh pathway as the 
following categories (Gonnissen et al., 2015; Ruat, 2015): 
inhibitors targeting Smo; strategies to target the upstream 
N-Shh ligand; and inhibitors targeting the downstream 
transcription factors Gli1 and Gli2 (Figure 3). The transla 
tion of these exciting new pharmacologic therapies to the 
treatment of kidney diseases has just begun in the preclini-
cal setting (Table 1). In this review, we will focus on the 
Table 1  The strategies to target Shh signaling in fibrotic CKDa) 
Disease model producing-cells  Responding cells Target/inhibitor Outcome References 
UUO Tubular cells Fibroblast Smo/cyclopamine Improved (Ding et al., 2012) 
IRI Tubular cells Fibroblast Smo/cyclopamine Improved (Zhou et al., 2014) 
UUO Tubular cells Pericyte/fibroblast Smo/IPI-926 Negative (Fabian et al., 2012) 
UUO Tubular cells Gli2/darinaparsin Improved (Kramann et al., 2015) 
UUO Tubular cells Pericyte/macrophage Smo/cyclopamine Improved (Rauhauser et al., 2015) 
a) UUO, unilateral ureteral obstruction. IRI, ischemia reperfusion injury 
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Figure 3  Therapeutic strategies to target Shh signaling pathway. The Shh 
signaling could be blocked at different levels, including Shh ligand inhibi-
tors, Smo receptor inhibitors and transcriptional factors Gli inhibitors. 
Among these antagonists, Smo inhibitors (cyclopamine and IPI-926) and 
Gli inhibitors (Darinaparsin and GANT61) are tested in the setting of fi-
brotic CKD. Except for IPI-926 (Fabian et al., 2012), all Shh signaling 
inhibitors are able to attenuate renal fibrosis in experimental models. 
Smo inhibitors and Gli inhibitors, which have been recently 
assessed for their efficacy in the treatment of kidney dis-
eases. 
 
Smo inhibitors  
The most common method to target Shh pathway is through 
manipulation of Smo activity because it is the main signal 
transducer of this pathway. Smo is responsible for a large 
variety of developmental processes. It belongs to class F 
(Frizzled family) of the G-protein-coupled receptor (GPCR) 
superfamily (Ruiz-Gomez et al., 2007). Recently, robust 
clinical investigations implicate Smo as a novel therapeutic 
target in human cancers.  
As the first member of a class of small molecular com-
pounds that specifically inhibit the activity of Smo, cyclo-
pamine (CPN) has been utilized in the treatment of experi-
mental renal fibrosis (Ding et al., 2012; Rauhauser et al., 
2015). CPN is a natural alkaloid derivative isolated from a 
plant of the corn lily family (Incardona et al., 1998; Strand 
et al., 2011). In renal fibrogenesis, targeting Smo with CPN 
inhibits fibroblast activation and matrix production in vitro, 
and it reduces matrix expression and mitigates fibrotic  
lesions in vivo after UUO and IRI (Ding et al., 2012; Zhou 
et al., 2014). Meanwhile, induction of the downstream tar-
get of Smo, Gli1 and Snail1, are largely abolished by CPN 
(Ding et al., 2012; Zhou et al., 2014). However, it does not 
affect upstream Shh ligand expression. The shortcomings of 
CPN are its short half-life and off-target effects at higher 
doses (Lipinski et al., 2008; Zhao et al., 2009). Therefore, a 
more soluble and potent CPN derivative, IPI-926 
(Saridegib), has been explored in clinical trials for basal cell 
carcinoma (BCC) and metastatic pancreatic cancer. After 
UUO, IPI-926 abolishes Gli1 induction, but not Gli2 in  
vivo, suggesting the existence of Smo-independent Gli acti-
vation in the model. In contrast to CPN, IPI-926 did not 
attenuate renal fibrosis (Fabian et al., 2012). These differ-
ences might be due to the chemical diversity of Smo modu-
lators and their different pharmacological properties,  
because there are at least two well-characterized ligand- 
binding pockets presented in Smo receptor: one in the  
extracellular domain (ECD), and one in the TM domain.  
The discovery of CPN and its derivative has heralded 
extensive research for development of Smo antagonist. A 
major breakthrough is the recent approval of a novel Smo 
antagonist Erivedge/Vismodegib (GDC-0449) in the Shh 
field by the FDA for treating metastatic BCC and locally 
advanced BCC deemed untreatable by surgery or radiation 
(Robarge et al., 2009). However, its effects in kidney  
diseases remain to be investigated and validated in the  
preclinical setting before considering any clinic trials.  
Gli inhibitors  
Although Smo has been considered as the most common 
target of Shh signaling, the importance of the downstream 
regulators of Smo, such as SuFu and Gli1/2 cannot be  
ignored. After all, Smo antagonists do not repress upstream 
ligands expression, whereas a compound directed against 
the downstream targets would be able to more effectively 
inhibit the entire pathway. In this regard, Darinaparsin, a 
novel organic arsenical with optimized pharmacokinetic 
properties, is currently in clinical studies for hematologic 
malignancies and solid tumors. As the antagonist of Gli 
proteins, Darinaparsin directly targets Gli2 protein and  
induces Gli-dependent cell-cycle arrest in renal myofibro-
blasts, thereby preventing myofibroblast proliferation and 
ameliorate kidney fibrosis in vivo (Kramann et al., 2015). 
Besides Darinaparsin, GANT61, a small-molecule inhibitor 
of Gli, also displayed the ability of ameliorating renal  
fibrosis in mice, even it is administered after injury 
(Kramann et al., 2015).  
SHH SIGNALING AND THE FIBROTIC 
DISEASE OF OTHER ORGANS  
Besides kidney, increasing evidence suggests that activation 
of Shh signaling is also associated with tissue fibrosis in 
other organs including lung and liver. In vitro, it has been 
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well documented that recombinant Shh protein induces an 
activated phenotype of cultured lung fibroblasts and hepatic 
stellate cells, as manifested by an augmented cell prolifera-
tion, migration, excessive ECM production (Hu et al., 2015; 
Yang et al., 2008). Shh signaling is upregulated in animal 
models and patients with idiopathic pulmonary fibrosis 
(IPF), other interstitial lung diseases and nonalcoholic fatty 
liver disease (NAFLD), with nuclear accumulation of Gli1, 
Gli2 in the fibrotic areas and an increased expression of the 
Shh downstream target genes. In lung, Shh is predominantly 
expressed in type II like epithelial cells of terminal bronchi-
oles and alveoli (Bolanos et al., 2012). Shh activation caus-
es aberrant epithelium-fibroblast interactions and directly 
triggers pulmonary fibrosis after injury (Hu et al., 2015; 
McGowan and McCoy, 2013). Unlike lung, Shh is found in 
both ballooned hepatocyte and hepatic stellate cells in the 
liver of NAFLD, which eventually leads to liver fibrosis or 
cirrhosis (Hirsova and Gores, 2015; Rangwala et al., 2011). 
By using hydrodynamics-based gene transfer approach, 
hepatic expression of Shh induces liver fibrosis, which is 
accompanied by concurrent activation of hepatic stellate 
cells, and upregulation of various fibrogenic genes (Chung 
et al., 2016). Meanwhile, hepatic stellate cells could  
produce Shh through an autocrine fashion to accelerate  
progression of liver diseases. In addition, activation of Shh 
signaling is also responsible for dermal fibrosis in systemic 
sclerosis (Horn et al., 2012). Therefore, activation of Shh 
signaling perhaps is a generalized mechanism leading to 
tissue fibrosis after injury.  
SUMMARY 
As a potent morphogen, Shh controls cell proliferation, dif-
ferentiation and morphogenesis in embryonic kidney (Yu et 
al., 2002). In the past few years, increasing evidence indi-
cates that re-activation of Shh signaling plays a critical role 
in the onset and progression of kidney fibrosis after various 
insults. Shh protein is produced and secreted by the injured 
tubules but specifically targets interstitial fibroblasts, lead-
ing to their activation, proliferation and expansion. Through 
such a paracrine fashion, Shh acts as a master communica-
tor and mediates epithelial-mesenchymal communication 
(EMC) during renal fibrogenesis. By characterizing the  
receptors, downstream regulators and transcriptional effec-
tors in the Shh signaling, pharmacologic manipulation of 
this pathway is now being attempted in a variety of animal 
models of CKD in preclinical setting.  
Our knowledge of Shh signaling remains in its infancy in 
the field of nephrology. Continuous exploration of renal 
pathogenesis linked with the Shh pathway and validation of 
pharmacological intervention strategies is an urgent task for 
researchers and nephrologists. There are many questions to 
be answered. For instance, since upregulation of Shh is an 
early event after injuries, what is the function of Shh in the 
setting of acute kidney injury? What is the role of Shh in 
glomerular diseases where the specialized epithelium  
(podocytes) communicates with mesangial cells? What is 
the extent of interaction between Shh and other pathologic 
signal pathways? It will be of great interest to see these dif-
ferent aspects of Shh signaling unveiled in the near future. 
Compliance and ethics  The author(s) declare that they have no conflict 
of interest. 
Acknowledgements  This work was supported by the National Natural 
Science Foundation of China (81130011, 81370839, 81521003), Guang-
dong Science Foundation (2014A030312014), Guangzhou Projects Grant 
(15020025), American Heart Association FTF (16990086), and National 
Institutes of Health Grants (DK064005, DK091239, DK106049). 
Aberger, F., Kern, D., Greil, R., and Hartmann, T.N. (2012). Canonical and 
noncanonical Hedgehog/GLI signaling in hematological malignancies. 
Vitam Horm 88, 25–54. 
Alfaro, A.C., Roberts, B., Kwong, L., Bijlsma, M.F., and Roelink, H. 
(2014). Ptch2 mediates the Shh response in Ptch1/ cells. Develop-
ment 141, 3331–3339. 
Bielesz, B., Sirin, Y., Si, H., Niranjan, T., Gruenwald, A., Ahn, S., Kato, 
H., Pullman, J., Gessler, M., Haase, V.H., and Susztak, K. (2010). Epi-
thelial Notch signaling regulates interstitial fibrosis development in the 
kidneys of mice and humans. J Clin Invest 120, 4040–4054. 
Bolanos, A.L., Milla, C.M., Lira, J.C., Ramirez, R., Checa, M., Barrera, L., 
Garcia-Alvarez, J., Carbajal, V., Becerril, C., Gaxiola, M., Pardo, A., 
and Selman, M. (2012). Role of Sonic Hedgehog in idiopathic pulmo-
nary fibrosis. Am J Physiol Lung Cell Mol Physiol 303, L978–990. 
Brennan, D., Chen, X., Cheng, L., Mahoney, M., and Riobo, N.A. (2012). 
Noncanonical Hedgehog signaling. Vitam Horm 88, 55–72. 
Carpenter, D., Stone, D.M., Brush, J., Ryan, A., Armanini, M., Frantz, G., 
Rosenthal, A., and de Sauvage, F.J. (1998). Characterization of two 
patched receptors for the vertebrate hedgehog protein family. Proc Natl 
Acad Sci USA 95, 13630–13634. 
Chinchilla, P., Xiao, L., Kazanietz, M.G., and Riobo, N.A. (2010). Hedge-
hog proteins activate pro-angiogenic responses in endothelial cells 
through non-canonical signaling pathways. Cell Cycle 9, 570–579. 
Chung, S.I., Moon, H., Ju, H.L., Cho, K.J., Kim, do Y., Han, K.H., Eun, 
J.W., Nam, S.W., Ribback, S., Dombrowski, F., Calvisi, D.F., and Ro, 
S.W. (2016). Hepatic expression of Sonic Hedgehog induces liver fi-
brosis and promotes hepatocarcinogenesis in a transgenic mouse model. 
J Hepatol 64, 618–627. 
Cigna, N., Farrokhi, Moshai, E., Brayer, S., Marchal-Somme, J., 
Wemeau-Stervinou, L., Fabre, A., Mal, H., Leseche, G., Dehoux, M., 
Soler, P., Crestani, B., and Mailleux, A.A. (2012). The hedgehog sys-
tem machinery controls transforming growth factor-beta-dependent 
myofibroblastic differentiation in humans: involvement in idiopathic 
pulmonary fibrosis. Am J Pathol 181, 2126–2137. 
Coresh, J., Selvin, E., Stevens, L.A., Manzi, J., Kusek, J.W., Eggers, P., 
Van Lente, F., and Levey, A.S. (2007). Prevalence of chronic kidney 
disease in the United States. JAMA 298, 2038–2047. 
Dai, P., Shinagawa, T., Nomura, T., Harada, J., Kaul, S.C., Wadhwa, R., 
Khan, M.M., Akimaru, H., Sasaki, H., Colmenares, C., and Ishii, S. 
(2002). Ski is involved in transcriptional regulation by the repressor and 
full-length forms of Gli3. Genes Dev 16, 2843–2848. 
Ding, H., Zhou, D., Hao, S., Zhou, L., He, W., Nie, J., Hou, F.F., and Liu, 
Y. (2012). Sonic hedgehog signaling mediates epithelial-mesenchymal 
communication and promotes renal fibrosis. J Am Soc Nephrol 23, 
801–813. 
Duffield, J.S. (2014). Cellular and molecular mechanisms in kidney fibro-
sis. J Clin Invest 124, 2299–2306. 
El-Zaatari, M., Zavros, Y., Tessier, A., Waghray, M., Lentz, S., Gumucio, 
D., Todisco, A., and Merchant, J.L. (2010). Intracellular calcium re-
lease and protein kinase C activation stimulate sonic hedgehog gene 
928 Zhou, D., et al.   Sci China Life Sci   September (2016) Vol.59 No.9 
expression during gastric acid secretion. Gastroenterology 139, 
2061–2071 e2062. 
Fabian, S.L., Penchev, R.R., St-Jacques, B., Rao, A.N., Sipila, P., West, 
K.A., McMahon, A.P., and Humphreys, B.D. (2012). Hedgehog-Gli 
pathway activation during kidney fibrosis. Am J Pathol 180, 
1441–1453. 
Gill, P.S., and Rosenblum, N.D. (2006). Control of murine kidney devel-
opment by sonic hedgehog and its GLI effectors. Cell Cycle 5, 
1426–1430. 
Gonnissen, A., Isebaert, S., and Haustermans, K. (2015). Targeting the 
Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotar-
get 6, 13899–13913. 
Grande, M.T., Sanchez-Laorden, B., Lopez-Blau, C., De Frutos, C.A., 
Boutet, A., Arevalo, M., Rowe, R.G., Weiss, S.J., Lopez-Novoa, J.M., 
and Nieto, M.A. (2015). Snail1-induced partial epithelial-to- 
mesenchymal transition drives renal fibrosis in mice and can be target-
ed to reverse established disease. Nat Med 21, 989–997. 
He, W., and Dai, C. (2015). Key fibrogenic signaling. Curr Pathobiol Rep 
3, 183–192. 
He, W., Dai, C., Li, Y., Zeng, G., Monga, S.P., and Liu, Y. (2009). 
Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am 
Soc Nephrol 20, 765–776. 
Hirsova, P., and Gores, G.J. (2015). Ballooned hepatocytes, undead cells, 
sonic hedgehog, and vitamin E: therapeutic implications for nonalco-
holic steatohepatitis. Hepatology 61, 15–17. 
Horn, A., Palumbo, K., Cordazzo, C., Dees, C., Akhmetshina, A., Tomcik, 
M., Zerr P., Avouac, J., Gusinde, J., Zwerina, J., Roudaut, H., Traiffort, 
E., Ruat, M., Distler, O., Schett, G., and Distler, J.H. (2012). Hedgehog 
signaling controls fibroblast activation and tissue fibrosis in systemic 
sclerosis. Arthritis Rheum 64, 2724–2733. 
Hu, B., Liu, J., Wu, Z., Liu, T., Ullenbruch, M.R., Ding, L., Henke, C.A., 
Bitterman, P.B., and Phan, S.H. (2015). Reemergence of hedgehog me-
diates epithelial-mesenchymal crosstalk in pulmonary fibrosis. Am J 
Respir Cell Mol Biol 52, 418–428. 
Incardona, J.P., Gaffield, W., Kapur, R.P., and Roelink, H. (1998). The 
teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog 
signal transduction. Development 125, 3553–3562. 
Ingham, P.W. (2012). Hedgehog signaling. Cold Spring Harb Perspect Biol 
4, a011221. 
Jenkins, D. (2009). Hedgehog signalling: emerging evidence for 
non-canonical pathways. Cell Signal 21, 1023–1034. 
Johnson, R.L., Milenkovic, L., and Scott, M.P. (2000). In vivo functions of 
the patched protein: requirement of the C terminus for target gene inac-
tivation but not Hedgehog sequestration. Mol Cell 6, 467–478. 
Kagawa, H., Shino, Y., Kobayashi, D., Demizu, S., Shimada, M., Ariga, 
H., and Kawahara, H. (2011). A novel signaling pathway mediated by 
the nuclear targeting of C-terminal fragments of mammalian Patched 1. 
PLoS One 6, e18638. 
Kang, H.M., Ahn, S.H., Choi, P., Ko, Y.A., Han, S.H., Chinga, F., Park, 
A.S., Tao, J., Sharma, K., Pullman, J., Bottinger, E.P., Goldberg, I.J., 
and Susztak, K. (2015). Defective fatty acid oxidation in renal tubular 
epithelial cells has a key role in kidney fibrosis development. Nat Med 
21, 37–46. 
Katoh, Y., and Katoh, M. (2008). Hedgehog signaling, epithelial-to-   
mesenchymal transition and miRNA. Int J Mol Med 22, 271–275. 
Katoh, Y., and Katoh, M. (2009). Hedgehog target genes: mechanisms of 
carcinogenesis induced by aberrant hedgehog signaling activation. Curr 
Mol Med 9, 873–886. 
Kramann, R., Fleig, S.V., Schneider, R.K., Fabian, S.L., DiRocco, D.P., 
Maarouf, O., Wongboonsin, J., Ikeda, Y., Heckl, D., Chang, S.L., 
Rennke, H.G., Waikar, S.S., and Humphreys, B.D. (2015). Pharmaco-
logical GLI2 inhibition prevents myofibroblast cell-cycle progression 
and reduces kidney fibrosis. J Clin Invest 125, 2935–2951. 
Kramann, R., Schneider, R.K., DiRocco, D.P., Machado, F., Fleig, S., 
Bondzie, P.A., Henderson, J.M., Ebert, B.L., and Humphreys, B.D. 
(2015). Perivascular Gli1+ progenitors are key contributors to inju-
ry-induced organ fibrosis. Cell Stem Cell 16, 51–66. 
Krauss, S., Concordet, J.P., and Ingham, P.W. (1993). A functionally con-
served homolog of the Drosophila segment polarity gene hh is ex-
pressed in tissues with polarizing activity in zebrafish embryos. Cell 75, 
1431–1444. 
Li, X., Deng, W., Lobo-Ruppert, S.M., and Ruppert, J.M. (2007). Gli1 acts 
through Snail and E-cadherin to promote nuclear signaling by be-
ta-catenin. Oncogene 26, 4489–4498. 
Li, Y., Wen, X., and Liu, Y. (2012). Tubular cell dedifferentiation and 
peritubular inflammation are coupled by the transcription regulator Id1 
in renal fibrogenesis. Kidney Int 81, 880–891. 
Lindstrom, E., Shimokawa, T., Toftgard, R., and Zaphiropoulos, P.G. 
(2006). PTCH mutations: distribution and analyses. Hum Mutat 27, 
215–219. 
Lipinski, R.J., Hutson, P.R., Hannam, P.W., Nydza, R.J., Washington, 
I.M., Moore, R.W., Girdaukas, G.G., Peterson, R.E., and Bushman, W. 
(2008). Dose- and route-dependent teratogenicity, toxicity, and phar-
macokinetic profiles of the hedgehog signaling antagonist cyclopamine 
in the mouse. Toxicol Sci 104, 189–197. 
Liu, Y. (2006). Renal fibrosis: new insights into the pathogenesis and 
therapeutics. Kidney Int 69, 213–217. 
Liu, Y. (2010). New insights into epithelial-mesenchymal transition in 
kidney fibrosis. J Am Soc Nephrol 21, 212–222. 
Liu, Y. (2011). Cellular and molecular mechanisms of renal fibrosis. Nat 
Rev Nephrol 7, 684–696. 
Lovisa, S., LeBleu, V.S., Tampe, B., Sugimoto, H., Vadnagara, K., Car-
stens, J.L., Wu, C.C., Hagos, Y., Burckhardt, B.C., Pentcheva-Hoang, 
T., Nischal, H., Allison, J.P., Zeisberg, M., and Kalluri, R. (2015). Epi-
thelial-to-mesenchymal transition induces cell cycle arrest and paren-
chymal damage in renal fibrosis. Nat Med 21, 998–1009. 
Lum, L., and Beachy, P.A. (2004). The Hedgehog response network: sen-
sors, switches, and routers. Science 304, 1755–1759. 
Makino, S., Masuya, H., Ishijima, J., Yada, Y., and Shiroishi, T. (2001). A 
spontaneous mouse mutation, mesenchymal dysplasia (mes), is caused 
by a deletion of the most C-terminal cytoplasmic domain of patched 
(ptc). Dev Biol 239, 95–106. 
McGowan, S.E., and McCoy, D.M. (2013). Platelet-derived growth fac-
tor-A and sonic hedgehog signaling direct lung fibroblast precursors 
during alveolar septal formation. Am J Physiol Lung Cell Mol Physiol 
305, L229–239. 
Meng, X.M., Tang, P.M., Li, J., and Lan, H.Y. (2015). TGF-beta/Smad 
signaling in renal fibrosis. Front Physiol 6, 82. 
Nieuwenhuis, E., Barnfield, P.C., Makino, S., and Hui, C.C. (2007). Epi-
dermal hyperplasia and expansion of the interfollicular stem cell com-
partment in mutant mice with a C-terminal truncation of Patched1. Dev 
Biol 308, 547–560. 
Nusslein-Volhard, C., and Wieschaus, E. (1980). Mutations affecting seg-
ment number and polarity in Drosophila. Nature 287, 795–801. 
O’Hara, W.A., Azar, W.J., Behringer, R.R., Renfree, M.B., and Pask, A.J. 
(2011). Desert hedgehog is a mammal-specific gene expressed during 
testicular and ovarian development in a marsupial. BMC Dev Biol 11, 
72. 
Ochi, H., Pearson, B.J., Chuang, P.T., Hammerschmidt, M., and Wester-
field, M. (2006). Hhip regulates zebrafish muscle development by both 
sequestering Hedgehog and modulating localization of Smoothened. 
Dev Biol 297, 127–140. 
Pan, A., Chang, L., Nguyen, A., and James, A.W. (2013). A review of 
hedgehog signaling in cranial bone development. Front Physiol 4, 61. 
Polizio, A.H., Chinchilla, P., Chen, X., Manning, D.R., and Riobo, N.A. 
(2011). Sonic Hedgehog activates the GTPases Rac1 and RhoA in a 
Gli-independent manner through coupling of smoothened to Gi pro-
teins. Sci Signal 4, pt7. 
Rangwala, F., Guy, C.D., Lu, J., Suzuki, A., Burchette, J.L., Abdelmalek, 
M.F., Chen, W., and Diehl, A.M. (2011). Increased production of sonic 
hedgehog by ballooned hepatocytes. J Pathol 224, 401–410. 
Rauhauser, A.A., Ren, C., Lu, D., Li, B., Zhu, J., McEnery, K., Vadnagara, 
K., Zepeda-Orozco, D., Zhou, X.J., Lin, F., Jetten, A.M., and Attanasio, 
M. (2015). Hedgehog signaling indirectly affects tubular cell survival 
after obstructive kidney injury. Am J Physiol Renal Physiol 309, 
F770-778. 
Reichrath, J., and Reichrath, S. (2013). The relevance of the vitamin D 
endocrine system (VDES) for tumorigenesis, prevention, and treatment 
 Zhou, D., et al.   Sci China Life Sci   September (2016) Vol.59 No.9 929 
of non-melanoma skin cancer (NMSC): present concepts and future 
perspectives. Dermatoendocrinol 5, 38–50. 
Robarge, K.D., Brunton, S.A., Castanedo, G.M., Cui, Y., Dina, M.S., 
Goldsmith, R., Gould, S.E., Guichert, O., Gunzner, J.L., Halladay, J., 
Jia, W., Khojasteh, C., Koehler, M.F., Kotkow, K., La H., Lalonde, 
R.L., Lau, K., Lee, L., Marshall, D., Marsters, J.C.Jr., Murray, L.J., 
Qian, C., Rubin, L.L., Salphati, L., Stanley, M.S., Stibbard, J.H., Suth-
erlin, D.P., Ubhayaker, S., Wang, S., Wong, S., and Xie, M. (2009). 
GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med 
Chem Lett 19, 5576–5581. 
Robbins, D.J., Fei, D.L., and Riobo, N.A. (2012). The Hedgehog signal 
transduction network. Sci Signal 5, re6. 
Ruat, M. (2015). The smoothened receptor in cancer and regenerative 
medicine. In Topics in Medicinal Chemistry (New York: Springer Ber-
lin Heidelberg).  
Ruiz-Gomez, A., Molnar, C., Holguin, H., Mayor, F.Jr., and de Celis, J.F. 
(2007). The cell biology of Smo signalling and its relationships with 
GPCRs. Biochim Biophys Acta 1768, 901–912. 
Santos, P.C., Krieger, J.E., and Pereira, A.C. (2012). Renin-angiotensin 
system, hypertension, and chronic kidney disease: pharmacogenetic 
implications. J Pharmacol Sci 120, 77–88. 
Strand, M.F., Wilson, S.R., Dembinski, J.L., Holsworth, D.D., Khvat, A., 
Okun, I., Petersen, D., and Krauss, S. (2011). A novel synthetic 
smoothened antagonist transiently inhibits pancreatic adenocarcinoma 
xenografts in a mouse model. PLoS One 6, e19904. 
Sweetwyne, M.T., Tao, J., and Susztak, K. (2014). Kick it up a notch: 
Notch signaling and kidney fibrosis. Kidney Int Suppl 4, 91–96. 
Tan, R.J., Zhou, D., Zhou, L., and Liu, Y. (2014). Wnt/beta-catenin sig-
naling and kidney fibrosis. Kidney Int Suppl 4, 84–90. 
Teperino, R., Aberger, F., Esterbauer, H., Riobo, N., and Pospisilik, J.A. 
(2014). Canonical and non-canonical Hedgehog signalling and the con-
trol of metabolism. Semin Cell Dev Biol 33, 81–92. 
Thibert, C., Teillet, M.A., Lapointe, F., Mazelin, L., Le Douarin, N.M., and 
Mehlen, P. (2003). Inhibition of neuroepithelial patched-induced apop-
tosis by sonic hedgehog. Science 301, 843–846. 
Tukachinsky, H., Lopez, L.V., and Salic, A. (2010). A mechanism for 
vertebrate Hedgehog signaling: recruitment to cilia and dissociation of 
SuFu-Gli protein complexes. J Cell Biol 191, 415–428. 
Wang, D., Dai, C., Li, Y., and Liu, Y. (2011). Canonical Wnt/beta-catenin 
signaling mediates transforming growth factor-beta1-driven podocyte 
injury and proteinuria. Kidney Int 80, 1159–1169. 
Yam, P.T., Langlois, S.D., Morin, S., and Charron, F. (2009). Sonic 
hedgehog guides axons through a noncanonical, Src-family-kinase- 
dependent signaling pathway. Neuron 62, 349–362. 
Yang, L., Wang, Y., Mao, H., Fleig, S., Omenetti, A., Brown, K.D., Sick-
lick, J.K., Li, Y.X., and Diehl, A.M. (2008). Sonic hedgehog is an auto-
crine viability factor for myofibroblastic hepatic stellate cells. J Hepatol 
48, 98–106. 
Yu, J., Carroll, T.J., and McMahon, A.P. (2002). Sonic hedgehog regulates 
proliferation and differentiation of mesenchymal cells in the mouse 
metanephric kidney. Development 129, 5301–5312. 
Zeisberg, M., and Neilson, E.G. (2010). Mechanisms of tubulointerstitial 
fibrosis. J Am Soc Nephrol 21, 1819–1834. 
Zhang, L., Wang, F., Wang, L., Wang, W., Liu, B., Liu, J., Chen, M., He, 
Q., Liao, Y., Yu, X., Chen, N., Zhang, J.E., Hu, Z., Liu, F., Hong, D., 
Ma, L., Liu, H., Zhou, X., Chen, J., Pan, L., Chen, W., Wang, W., Li, 
X., and Wang, H. (2012). Prevalence of chronic kidney disease in Chi-
na: a cross-sectional survey. Lancet 379, 815–822. 
Zhao, C., Chen, A., Jamieson, C.H., Fereshteh, M., Abrahamsson, A., 
Blum, J., Kwon, H.Y., Kim, J., Chute, J.P., Rizzieri, D., Munchhof, M., 
VanArsdale, T., Beachy, P.A., and Reya, T. (2009). Hedgehog signal-
ling is essential for maintenance of cancer stem cells in myeloid leu-
kaemia. Nature 458, 776–779. 
Zhao, Q., Beck, A., and Fraidenraich, D. (2010). A direct, non-canonical 
pathway for Hedgehog proteins in the endothelium. Cell Cycle 9, 
647–648. 
Zhao, X.P., Liao, M.C., Chang, S.Y., Abdo, S., Aliou, Y., Chenier, I., 
Ingelfinger, J.R., and Zhang, S.L. (2014). Maternal diabetes modulates 
kidney formation in murine progeny: the role of hedgehog interacting 
protein (HHIP). Diabetologia 57, 1986–1996. 
Zhou, D., Li, Y., Zhou, L., Tan, R.J., Xiao, L., Liang, M., Hou, F.F., and 
Liu, Y. (2014). Sonic hedgehog is a novel tubule-derived growth factor 
for interstitial fibroblasts after kidney injury. J Am Soc Nephrol 25, 
2187–2200. 
Zhou, D., Li, Y., Lin, L., Zhou, L., Igarashi, P., and Liu, Y. (2012). Tu-
bule-specific ablation of endogenous beta-catenin aggravates acute 
kidney injury in mice. Kidney Int 82, 537–547. 
Zhou, D., and Liu, Y. (2016). Renal fibrosis in 2015: understanding the 
mechanisms of kidney fibrosis. Nat Rev Nephrol 12, 68–70. 
Zhou, D., Tan, R.J., Fu, H., and Liu, Y. (2016). Wnt/beta-catenin signaling 
in kidney injury and repair: a double-edged sword. Lab Invest 96, 
156–167. 
Zhou, L., Li, Y., Hao, S., Zhou, D., Tan, R.J., Nie, J., Hou, F.F., Kahn, M., 
and Liu, Y. (2015). Multiple genes of the renin-angiotensin system are 
novel targets of Wnt/beta-catenin signaling. J Am Soc Nephrol 26, 
107–120. 
Zhou, L., and Liu, Y. (2015). Wnt/beta-catenin signalling and podocyte 
dysfunction in proteinuric kidney disease. Nat Rev Nephrol 11, 
535–545. 
Zhulyn, O., Nieuwenhuis, E., Liu, Y.C., Angers, S., and Hui, C.C. (2015). 
Ptch2 shares overlapping functions with Ptch1 in Smo regulation and 
limb development. Dev Biol 397, 191–202. 
Zoccali, C., Kramer, A., and Jager, K.J. (2010). Epidemiology of CKD in 
Europe: an uncertain scenario. Nephrol Dial Transplant 25, 1731–1733. 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
